12:00 AM
 | 
Jan 09, 2006
 |  BioCentury  |  Strategy

Phase III options

Phase III options

Companies Product Indication Up front Milestones Royalties U.S. rights Other terms
Nuvelo (NUVO)/ Bayer (FSE:BAYG; BAY) Alfimeprase Peripheral arterial...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >